Genetic Inhibition of the Ubiquitin Ligase Rnf5 Attenuates Phenotypes Associated to F508del Cystic Fibrosis Mutation by Tomati, V. (Valeria) et al.
1Scientific RepoRts | 5:12138 | DOi: 10.1038/srep12138
www.nature.com/scientificreports
Genetic Inhibition Of The 
Ubiquitin Ligase Rnf5 Attenuates 
Phenotypes Associated To F508del 
Cystic Fibrosis Mutation
Valeria Tomati1, Elvira Sondo1, Andrea Armirotti2, Emanuela Caci1, Emanuela Pesce1, 
Monica Marini1, Ambra Gianotti1, Young Ju Jeon3, Michele Cilli4, Angela Pistorio1, 
Luca Mastracci4,5, Roberto Ravazzolo1,6, Bob Scholte7, Ze’ev Ronai3, Luis J. V. Galietta1 & 
Nicoletta Pedemonte1
Cystic fibrosis (CF) is caused by mutations in the CFTR chloride channel. Deletion of phenylalanine 
508 (F508del), the most frequent CF mutation, impairs CFTR trafficking and gating. F508del-
CFTR mistrafficking may be corrected by acting directly on mutant CFTR itself or by modulating 
expression/activity of CFTR-interacting proteins, that may thus represent potential drug targets. To 
evaluate possible candidates for F508del-CFTR rescue, we screened a siRNA library targeting known 
CFTR interactors. Our analysis identified RNF5 as a protein whose inhibition promoted significant 
F508del-CFTR rescue and displayed an additive effect with the investigational drug VX-809. 
Significantly, RNF5 loss in F508del-CFTR transgenic animals ameliorated intestinal malabsorption and 
concomitantly led to an increase in CFTR activity in intestinal epithelial cells. In addition, we found 
that RNF5 is differentially expressed in human bronchial epithelia from CF vs. control patients. Our 
results identify RNF5 as a target for therapeutic modalities to antagonize mutant CFTR proteins.
Cystic Fibrosis (CF), one of the most common inherited diseases (~1/3000 in Caucasian populations), 
is caused by mutations in the gene encoding the CF transmembrane conductance regulator (CFTR), a 
cAMP-regulated chloride channel expressed at the apical membrane of many types of epithelial cells1,2. In 
the airways, defective CFTR function alters electrolyte/water transport in several ways. The low chloride 
transport causes impaired hydration, and reduced bicarbonate secretion affects mucus viscosity, release 
and detachment3–5. Concomitant activity of the epithelial sodium channel (ENaC) drives sodium/fluid 
absorption thus leading to further dehydration of the epithelial surface. Consequent depletion of the 
periciliary fluid (PCF) causes the arrest of mucociliary transport6, enabling bacteria to colonize airways. 
Persistence of bacteria in the lung triggers a severe inflammatory response accompanied by progressive 
loss of respiratory function. Impaired anion transport seen in CF also perturbs function of the pancreas, 
liver, sweat glands, and reproductive system.
The most common CF mutation, the deletion of phenylalanine 508 (F508del), is responsible for two 
distinct defects: 1) a processing defect, that is, misfolding of the F508del-CFTR protein, which causes 
its retention at the endoplasmic reticulum (ER) and premature degradation by the ubiquitin/proteasome 
system7–11; and 2) a channel gating defect due to abnormal persistence of a closed state12–15. Several 
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studies have assessed the suitability of F508del-CFTR as a target for pharmacotherapy. Noteworthy, both 
F508del defects can be rescued in vitro using specific small molecules, and thus the defective channel is 
considered “druggable”. In particular, the gating defect is partially ameliorated by “potentiators”, defined 
as compounds that acutely stimulate channel activity. Other molecules of interest, known as “correc-
tors”, improve processing or folding of F508del mutant protein16. To date, various correctors have been 
identified; how they function is unknown, although they may act directly on mutant CFTR itself or 
on proteins in the CFTR interactome. Recently, F508del correctors were grouped into three classes17. 
Class 1 correctors improve the interaction between separate domains of CFTR protein, in particular 
between the nucleotide-binding domain 1 (NBD1) and the cytosolic loop 4 (CL4). The investigational 
drug VX-80918 belongs to this first group of compounds. Class 2 compounds likely interact with the 
second nucleotide-binding domain (NBD2). Class 3 correctors, which essentially include chemical chap-
erones like glycerol, directly stabilize NBD1, a particularly important effect since the F508del mutation is 
located in this domain17. Importantly, it has been shown that the use of a single corrector is not sufficient 
to promote a marked F508del rescue17, suggesting that combinations of correctors will be required to 
achieve a therapeutic effect.
An alternative way to rescue F508del-CFTR is to modify the proteostasis environment by modulating 
the function of protein(s) involved in quality control or degradation of CFTR in the ER or plasma mem-
brane19,20. Various studies have identified proteins that likely function in F508del-CFTR mistrafficking 
and could thus represent useful drug targets. Among them, the ubiquitin ligase RMA1/RNF5 is particu-
larly relevant as it acts at early stages of CFTR biosynthesis and its loss by gene silencing synergizes with 
a pharmacological corrector to correct folding defects21. Therefore, RNF5 pharmacological inhibition 
could represent an important strategy to rescue CFTR function in CF patients carrying the F508del allele.
Comparison of RNF5 with other potential therapeutic targets has not been undertaken, particularly 
in a relevant airway/epithelial background. Here, using functional and biochemical assays, we report that 
RNF5 silencing results in rescue of F508del-CFTR phenotypes comparable to or better than that obtained 
by targeting other proteins associated with F508del-CFTR mistrafficking and degradation. As validation 
of RNF5 suitability in vivo, we evaluated the effect of RNF5 knockout in transgenic mice expressing 
F508del-CFTR. RNF5 knockout F508del-CFTR mice exhibited improved intestinal absorption relative 
to animals expressing wild-type RNF5, as demonstrated by reduced frequency of animals with severely 
decreased body weight and reduced fecal excretion of biliary acids. These studies point to potential use 
of RNF5 as a novel target for F508del-CFTR.
Results
Using information from the literature and data available in the BIOGRID Protein Interaction Database, 
we generated a list of proteins that potentially play a key role in F508del-CFTR processing and degrada-
tion. We included proteins with known interaction with CFTR, such as RNF5/RMA1, CHIP, DERLIN-1, 
p97/VCP, and CAL22–25. The list was expanded by adding macromolecules belonging to the sumoyla-
tion pathway, a process demonstrated to function in CFTR degradation26. We also included proteins 
identified in gene expression profiles of bronchial epithelial cells treated with F508del correctors27. For 
example, ciclopirox, which acts as a F508del-CFTR corrector in CFBE41o- cells27, is an iron-chelating 
agent and, consequently, inducer of the hypoxia-inducible factor 1 cascade28. Consequently, we also 
included hypoxia-related proteins such as VHL, cullin-2 and the prolyl hydroxylase domain (PHD) pro-
teins EGLN-1, -2 and -3. Procollagen prolyl 4-hydroxylases (P4Hs) were included as a control, given that 
PHDs likely utilize a mechanism similar to that of P4Hs29 and based on the report that P4HA1 interacts 
with CFTR30. Among additional controls, we included members of the anion channels and transport-
ers TMEM16 and SLC26 protein families31,32. We then generated a specific library of short interfering 
RNAs (siRNAs) including 3–4 siRNAs per target. CFBE41o- bronchial epithelial cells exhibiting stably 
co-expressing F508del-CFTR and the halide-sensitive yellow fluorescent protein (HS-YFP) were trans-
fected with each siRNA separately. After 48 hours, F508del-CFTR activity in the plasma membrane was 
assessed by measuring the rate of HS-YFP quenching caused by iodide influx into cells33. As a positive 
control, we treated cells with the investigational drug corrector VX-80918.
Figure  1A summarizes results of the siRNA library screening. Interestingly, we found a significant 
increase in anion transport based on assessment of HS-YFP quenching following knockdown of some, 
but not all, targets proposed to function in F508del-CFTR trafficking and degradation. Effectiveness of 
silencing of specific targets was verified by evaluating target mRNA level using real-time quantitative PCR. 
For example, silencing of RNF5/RMA1 or DERLIN-1 (silencing achieved 90% and 83%, respectively) 
elicited a 70–80% increase in F508del-CFTR function over control-transfected cells. RNF5/RMA1 is a 
ubiquitin E3 ligase responsible for F508del-CFTR degradation at very early steps21. DERLIN-1  recognizes 
misfolded, non-ubiquitylated CFTR to initiate its dislocation and degradation early in the course of CFTR 
biogenesis23. We also observed significant rescue following transfection with siRNAs against NEDD4L, a 
ubiquitin ligase that regulates ENaC surface expression or internalization downstream of SGK134. Other 
targets previously associated with F508del-CFTR were not confirmed in our screen, possibly due to poor 
knockout efficiency. For example, transfection with siRNAs against CHIP, a ubiquitin ligase downstream 
of RNF535, did not result in rescue of F508del-CFTR trafficking defect. Similar negative results were found 
for AHA-1, an Hsp90 co-chaperone previously identified as an important target for F508del-CFTR res-
cue30. We also tested histone deacetylase 7 (HDAC-7; silencing achieved 78%), a target of the corrector 
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Figure 1. Rescue of F508del-CFTR by gene silencing. The bar graph shows F508del-CFTR activity in 
CFBE41o- cells based on a YFP assay after transfection with siRNAs (10 nM final concentration) against 
indicated targets or with control, non-targeting (NT) siRNA (10 nM siRNA in all conditions). The activity 
measured upon treatments was normalized for the activity detected under control condition (NT-siRNA + 
DMSO). The assay was carried out 48 hours after transfection. Cells were incubated at 37 °C prior to analysis. 
Data are expressed as means ± SEM, n = 8. Statistical significance was tested by parametric ANOVA followed 
by the Dunnet multiple comparisons test (all groups against the control group). Symbols indicate statistical 
significance versus NT-siRNA: **P < 0.01, *P < 0.05; or versus NT-siRNA + VX-809: §§P < 0.01, §P < 0.05. A. 
Results of siRNA library screening. B. Additivity of target silencing with VX-809. Bar graph shows results of 
combined treatment with vehicle alone (DMSO, white bar) or VX-809 (1 μ M; gray bars) of cells transfected 
with different siRNAs.
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SAHA36, and, as a negative control, we included another histone deacetylase, HDAC-9. Intriguingly, we 
observed increased anion transport following silencing of HDAC-9 but not HDAC-7.
Among promising targets, we found several proteins functioning in the sumoylation pathway. Indeed, 
silencing of UBE2I/UBC9 (the primary SUMO E2 conjugating enzyme; silencing achieved 97%) signifi-
cantly rescued F508del-CFTR protein (80% increase in CFTR activity relative to control cells). Silencing 
of CBX4, PIAS3 (both SUMO E3 ligases; silencing achieved 87% and 88%, respectively) or SUMO-4 
was also effective in increasing anion transport (80%, 60% and 30% increase, respectively). These data 
confirm the role of sumoylation in F508del-CFTR processing, as described by Frizzell and colleagues26. 
Silencing of PSMD2, a proteasome subunit (silencing achieved 88%), resulted in variable degrees of 
F508del-CFTR rescue, ranging from no effect to a 60–65% increase in F508del-CFTR activity relative to 
control-transfected cells.
As an independent control we evaluated the effect of NHERF-1 knockdown. NHERF-1 report-
edly stabilizes CFTR at the plasma membrane via direct interaction with the CFTR C-terminus37–39. 
Anti-NHERF-1 siRNAs promoted a significant decrease in F508del-CFTR activity.
Given that combinations of rescue maneuvers (e.g. pairs of correctors or pairs of revertant muta-
tions having different mechanism of action) are required to generate substantial corrective effects on 
F508del-CFTR activity17,40–42, we asked whether combining gene silencing with treatment with the cor-
rector VX-809 would result in additive or synergistic effects. Therefore, we transfected CFBE41o- cells 
with siRNAs and the following day, we treated silenced cells with either vehicle (DMSO) or the correc-
tor VX-809. After additional 24 hours, F508del-CFTR activity in the plasma membrane was measured 
using the YFP assay. As shown in Fig.  1B, rescue of F508del-CFTR activity by VX-809 treatment was 
enhanced by loss of specific targets, the most effective being a combination of VX-809 with UBC9 or 
RNF5 knockdown. Under these conditions, anion transport activity in F508del-CFTR cells markedly 
increased. Indeed, silencing of UBC9 plus VX-809 caused a 380% increase (relative to cells treated with 
NT-siRNA plus vehicle), and a 210% increase (relative to cells treated with NT-siRNA plus VX-809) 
in CFTR-mediated anion transport, while silencing of RNF5 plus VX-809 determined a 310% increase 
(relative to cells treated with NT-siRNA plus vehicle), and a 140% increase (relative to cells treated with 
NT-siRNA plus VX-809) in F508del-CFTR activity.
We also assessed rescue phenotypes biochemically by observing the electrophoretic mobility of CFTR 
protein. On Western blots, CFTR protein is detected as two bands, named B and C, of approximately 150 
and 170 kDa, respectively. Band B corresponds to partially glycosylated CFTR residing in the ER. Band 
C is instead the mature fully processed CFTR that has passed through the Golgi33. The prevalent form 
in cells expressing wild-type CFTR is band C. Cells expressing F508del-CFTR express primarily band 
B, consistent with severe trafficking defects caused by the mutation (Fig. 2A). To evaluate the effect of 
target knockdown on CFTR electrophoretic mobility, we transfected CFBE41o- cells with siRNAs and 
after 24 hours we treated silenced cells with VX-809 (or vehicle). The following day, cells were lysed and 
lysates were subjected to SDS-page followed by western blotting. Western blot images were analyzed with 
ImageJ software. For each lane, CFTR bands, analyzed as ROI, were quantified after normalization for 
actin to account for total protein loading and expressed as relative abundance with respect to band B 
observed in control cells. Treatment of F508del cells with siRNAs targeting PIAS3 or RNF5 significantly 
enhanced expression of immature CFTR (band B), while UBC9 knockdown enhanced expression of 
both immature and mature CFTR without changing the relative ratio of band C to band B (Fig. 2A,B). 
Incubation of cells for 24 hours with VX-809 was the only treatment that elicited a significant 2-fold 
increase in C/B band ratio. Combining VX-809 treatment with DERLIN-1 silencing further increased the 
intensity of band B, while VX-809 treatment combined with either UBC9 or PIAS3 silencing increased 
both band B and band C intensity relative to cells treated with VX-809 alone without changing the C/B 
ratio (Fig. 2A,B). Interesting, silencing of RNF5 in combination with VX-809 treatment caused a modest 
increase in intensity of bands B and C relative to VX-809 treatment alone, although that change was not 
statistically significant (Fig. 2B). This result contrasts with our functional data showing a strong additive 
effect of VX-809 combined with RNF5 silencing (Fig. 1B). Therefore, we performed cell surface biotinyla-
tion experiments to assess which form of CFTR is expressed at the plasma membrane. In cells expressing 
wild-type CFTR, the mature form was prevalent (Fig. 3A), while cells expressing F508del-CFTR expressed 
significant levels of immature CFTR on their surface. Importantly, levels of immature CFTR available 
for biotinylation were markedly increased following RNF5 knockdown (Fig. 3A). In contrast, treatment 
with VX-809 only promoted the appearance of mature CFTR. Combined VX-809 plus anti-RNF5 siRNA 
treatment had an additive effect: the intensity of bands B and C increased (Fig. 3A).
To evaluate mechanisms underlying the effect of RNF5 inhibition on enhanced cell surface expres-
sion of mutant CFTR we assessed the potential role of the non-canonical export pathway governed by 
GRASP family proteins GRASP55 and GRASP65, which are implicated in trafficking of the immature 
CFTR to the plasma membrane43. To do so, we used GRASP55 and GRASP65 knockdown by siRNA 
molecules to ask whether rescue of F508del-associated phenotypes caused by RNF5 silencing was medi-
ated by the GRASP system. Notably, silencing of GRASP65 (silencing achieved 71%) diminished the 
amount of immature CFTR (band B) expressed at the membrane as assessed by electrophoretic mobility 
of biotinylated CFTR protein (Fig. 3B) and markedly decreased RNF5 knockdown-dependent rescue of 
F508del-CFTR function as assessed by halide transport measurements (Fig. 3C). Interestingly, GRASP65 
silencing also decreased basal CFTR activity in control cells, suggesting that basal activity of this pathway 
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Figure 2. Biochemical analysis of the F508del-CFTR expression pattern. Shown is electrophoretic mobility 
of F508del-CFTR in CFBE41o- cells after transfection with indicated siRNAs (30 nM final concentration) in 
combination with treatment with vehicle alone (DMSO) or VX-809 (1 μ M). Cells were reverse-transfected 
with siRNA and cultured for 24 h at 37 °C and then treated with DMSO or VX-809 for an additional 24 h. 
A. Immunoblot detection of CFTR. Arrows indicate complex-glycosylated (band C) and core-glycosylated 
(band B) forms of CFTR protein. B. Quantification of CFTR bands. Left panels: data are expressed as relative 
abundance of band B (white bars) and band C (black bars), normalized for abundance of band B in cells 
treated with NT-siRNA + DMSO (top panel) or NT-siRNA + VX-809 (bottom panel). Data are expressed as 
means ± SEM, n = 3–5 independent experiments. Statistical significance was tested by parametric ANOVA 
followed by the Dunnet multiple comparisons test (all groups against the control group). Symbols indicate 
statistical significance versus NT-siRNA band B: **P < 0.01, *P < 0.05; or versus NT-siRNA band C: §§P < 0.01, 
§P < 0.05. Right panels: graphs reporting the C/B band ratio for data shown in left panels.
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Figure 3. Cell surface expression of complex- and core-glycosylated CFTR. Detection by cell surface 
biotinylation of F508del-CFTR forms expressed at the plasma membrane. CFBE41o- cells were transfected 
with indicated siRNAs (30 nM final concentration) and treated with and without VX-809 (1 μ M). A,B. 
Immunoblot detection of CFTR and control proteins in the biotinylated fraction (left) and in total lysates 
(right). Arrows indicate the complex-glycosylated form (band C) and core-glycosylated form (band B). 
Absence of the cytosolic proteins calnexin (CNX) and 14-3-3 in the biotinylated fraction confirms surface 
protein-specific labeling in each experiment. C. The bar graphs show F508del-CFTR activity in CFBE41o- 
cells (based on a YFP assay) after transfection with indicated siRNAs (10 nM final concentration) combined 
with treatment with vehicle alone (DMSO; left graph) or VX-809 (1 μ M; right graph). The activity measured 
upon treatments was normalized for the activity detected under control condition (NT-siRNA + DMSO). 
Data are expressed as means ± SEM, n = 8 per experiment. Reproducibility of results was confirmed by 
performing three independent experiments. Statistical significance was verified by ANOVA followed by the 
Tukey test (for multiple comparisons). Symbols indicate statistical significance versus the respective control.
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in CFBE41o− cells is involved in plasma membrane expression of immature CFTR (Fig. 3B,C). GRASP65 
suppression also significantly decreased the extent of CFTR rescue obtained following combined RNF5 
silencing and VX-809 treatment (Fig. 2D). GRASP55 silencing (silencing achieved 87%) was less effec-
tive (Fig.  3C), indicating that in CFBE41o− cells the primary protein functioning in unconventional 
F508del-CFTR trafficking is GRASP65.
Our data, obtained in a bronchial epithelial cell line, indicated RNF5 may indeed be an important 
therapeutic target for rescue of F508del-CFTR. We thus set to confirm our initial observations using a 
native cell system. Our attempts to use primary cultures of human bronchial epithelial cells did not suc-
ceed, largely due to the very low efficiency of target knockdown in these cultures. We thus set to further 
assess the importance of RNF5 in genetic mouse models, using mice expressing the F508del mutant 
transgene (Cftrtm1eur)44–46 and Rnf5−/− mice, all on a C57BL/6J genetic background. RNF5 knockout 
animals were generated by replacing the first 3 exons of the Rnf5 gene with the Neomycin cassette47. 
Rnf5−/− mice exhibit reduced and delayed activation of ER stress markers, compared with wild-type 
animals47. We then crossed Rnf5−/− mice with transgenic mice bearing the F508del mutation, thereby 
generating animals that express F508del-CFTR (or wild-type counterpart), with and without RNF5.
Lack of functional CFTR in mice mostly results in abnormalities of the gastrointestinal tract, includ-
ing obstruction and malabsorption, and reduced body weight46,48,49, common characteristics observed 
in all CF mouse models46. On the contrary, the mortality due to CF pathology is more variable46. In 
our strain, the survival-to-maturity rate is >85%46. As an important readout of the disease, we analyzed 
mice body weight. Assessment of body weight was performed in nine-day-old mice. We chose to ana-
lyze mouse body weight at 9 days because at earlier stages breastfeeding causes marked weight fluctua-
tions (up to 20% of mouse body weight). In addition, mortality, although low, affects primarily CF pups 
with the most severe phenotype, hampering long-term studies. Our analysis revealed, as expected, that 
the mean body weight of wild-type RNF5/homozygous F508del-CFTR (RNF5WT/CFTR∆F508) ani-
mals was 25% lower than that of wild-type RNF5/wild-type CFTR (RNF5WT/CFTRWT) mice (Fig. 4A 
and Table 1). The body weight of RNF5KO/CFTR∆F508 mice was not significantly greater than that of 
RNF5WT/CFTR∆F508 mice. Homoscedasticity of mouse body weight distributions was verified by using 
the Hartley Fmax test, resulting in a significant difference between the variance of RNF5WT/CFTR∆F508 
and RNF5KO/CFTR∆F508 groups (P = 0.029). The quantitative variable “Weight” was dichotomized 
between mice with RNF5 presence or absence (RNF5WT/CFTR∆F508 and RNF5KO/CFTR∆F508, 
respectively) using the analysis of the ROC curve method; a cut-off value of ≤ 2.9 g (i.e. < 3 g) was 
obtained. Notably, all the RNF5KO/CFTR∆F508 animals weighed more than 3 g, similar to CFTRWT 
mice (Table 1). By contrast, about 27% of RNF5WT/CFTR∆F508 animals weighed less than 3 g (circle 
in Fig. 4A and Table 1). Comparison of frequencies of animals with body weight < 3 g between the two 
groups (RNF5WT/CFTR∆F508 vs. RNF5KO/CFTR∆F508) was performed by means of the Fisher’s Exact 
test and Bonferroni’s correction. The analysis confirmed that the difference in frequencies is statistically 
significant (P = 0.00324; P(B) = 0.00647; **). We asked whether there was a difference in the frequency 
of animals weighting < 3 g between RNF5WT/CFTR∆F508 animals having one or two RNF5 wild-type 
alleles (mice with Rnf5 genotype +/− or +/+, respectively). We found that the frequencies of animals with 
body weight < 3 g were very similar for the two groups (25.0% and 28.6% for Rnf5 +/− and +/+, respec-
tively), suggesting that complete RNF5 knockout is required to see the beneficial effect on body weight.
As a second readout of the pathology, we measured the extent of biliary acid (primary, secondary and 
conjugates) excretion in feces of animals of different genotypes using liquid chromatography-electrospray 
tandem mass spectrometry. The concentration of primary biliary acids and conjugated biliary acids (bile 
salts) excreted in feces of RNF5WT/CFTRWT mice was similar to that of RNF5KO/CFTRWT mice 
(Table  2). As reported previously for FVB Cftr KO and FVB Cftrtmieur mice48, RNF5WT/CFTR∆F508 
mice exhibited greater excretion of total primary biliary acids and bile salts in stools, than did RNF5WT/
CFTRWT (P < 0.01; see Table 2). However, in RNF5KO/CFTR∆F508 mice, we observed decreased excre-
tion of total primary and conjugated bile acids with respect to RNF5WT/CFTR∆F508 mice (Table  2). 
The most abundant taurine-conjugated biliary salts in mice feces are taurocholic, taurodeoxycholic and 
taurochenodeoxycholic acids. While levels of the latter did not vary in mice of different genotypes, tau-
rocholic and taurodeoxycholic acid levels showed the same trend as that described for total bile salts 
excretion (Table  2 and Fig.  4B). Similar trends were observed for the glycine-conjugated biliary salt 
glycocholic acid, and for the two primary bile acids, cholic acid and chenodeoxycholic acid (Table 2 and 
Fig.  4B). Such decreases in bile salts excreted in feces demonstrate that in vivo RNF5 suppression can 
improve intestinal absorption in CF mice.
We next asked whether increased intestinal absorption observed in RNF5KO/CFTR∆F508 mice 
is due to increased CFTR activity and sought to characterize ion transport properties of duodenum 
epithelium from RNF5WT/CFTRWT, RNF5WT/CFTR∆F508 and RNF5KO/CFTR∆F508 mice. To do 
so, we performed Ussing chamber experiments (Fig.  5A,B). In RNF5WT/CFTRWT animals, addition 
of the cAMP-elevating agent forskolin to the serosal side of tissue induces a negative shift in transe-
pithelial potential difference (and therefore in the equivalent short-circuit current) reportedly due to 
cAMP-dependent activation of the apical CFTR and of the basolateral potassium channel KCNQ1/
KCNE3, which enables recycling of potassium through the basolateral membrane and maintenance of 
membrane potential favorable to chloride efflux (Fig.  5A). Subsequent addition of chromanol 293B to 
the basolateral side of the epithelium to block KCNQ1/KCNE3 channels inhibits anion secretion50. As 
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Figure 4. In vivo effect of RNF5 suppression in a CF mouse model. A. Mouse body weight. Graph 
shows body weight of 9-day-old littermates (males and females) grouped according to the genotype, as 
indicated in Methods section. Lines indicate mean values for each group. The quantitative variable “Weight” 
was dichotomized between mice with RNF5 presence or absence (RNF5WT/CFTR∆F508 and RNF5KO/
CFTR∆F508, respectively), and ROC curve anaysis identified a cut-off value of ≤2.9 g (i.e. <3 g). The circle 
indicates the fraction (26.9% of total) of RNF5WT/CFTR∆F508 mice exhibiting severely reduced body 
weight (< 3 g). Comparison of frequencies of mice with body weight less than 3 grams was performed 
based on the Fisher’s exact test (as the expected frequencies were less than 5), followed by Bonferroni’s 
correction. Symbols indicate statistical significance versus the RNF5KO/CFTR∆F508 mice group: **P < 0.01. 
B. Fecal biliary acid excretion. Graphs show the extent of fecal excretion of indicated biliary acids in mice 
of different genotypes (as for body weight). Lines indicate median values for each group. Littermates are 
males and females, 15 to 18 weeks of age on a C57BL/6J genetic background. Comparison of values was 
performed using the non-parametric Kruskal-Wallis ANOVA test, followed by the Mann-Whitney U test 
and Bonferroni’s correction. Symbols indicate statistical significance versus the RNF5WT/CFTRWT mice 
group: **P < 0.01; or versus RNF5WT/CFTR∆F508: §P < 0.05.
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expected, the ∆Isc value for cAMP-induced CFTR-mediated chloride secretion in RNF5WT/CFTR∆F508 
mice was minimal and equivalent to < 4% the current measured in controls (0.34 ± 0.06 μ A vs. 9.1 ± 1 
μ A in RNF5WT/CFTRWT animals).
In contrast, RNF5KO/CFTR∆F508 mice showed a significant cAMP-induced response (1.7 ± 0.5 μ A) 
with a 5-fold-increase in chloride secretion, equivalent to 18.7% the current measured in controls 
(Fig. 5B). As for the body weight, we asked whether the ∆Isc value for cAMP-induced CFTR-mediated 
chloride secretion varied between RNF5WT/CFTR∆F508 animals having one or two RNF5 wild-type 
alleles (mice with Rnf5 genotype +/− or +/+, respectively). We found that cAMP-induced responses were 
very similar for the two groups (0.3 ± 0.1 μ A and 0.35 ± 0.08 μ A for Rnf5 +/− and +/+, respectively), sug-
gesting that complete RNF5 knockout is required to see a 5-fold-increase in CFTR-mediated chloride 
secretion.
These results confirm that phenotypes attributable to CFTR∆F508 can be attenuated in vivo by RNF5 
ablation, even in the absence of VX-809 treatment.
A deregulation of RNF5 expression and localization was observed in certain human myopathies 
associated with ER impairment, such as inclusion body myositis47, but also in some cancers51 and in 
Parkinson’s disease52. To assess whether RNF5 protein is differentially expressed/localized in human 
Group 1 Group 2 Group 3 Group 4
RNF5WT/CFTRWT RNF5WT/CFTR∆F508 RNF5KO/CFTRWT RNF5KO/CFTR∆F508
N. Mice 59 26 101 29
Body weight (g): 
Mean (sem) 4.74 (0.11) 3.84 (0.18) 4.78 (0.07) 3.91 (0.11)
Body weight (g): 
Median (min–
max)
4.7 (3.2–6.6) 4.0 (1.9–5.4) 4.8 (3.1–6.6) 4.0 (3.0–5.2)
N. Mice with body 
weight < 3 g (%) 0 (0%) 7 (26.9%)
** 0 (0%) 0 (0%)
Table 1.  Body weight of 9-day-old mice with different genotypes. Littermates are males and females, 
of C57BL/6J genetic background. The quantitative variable “Weight” was dichotomized between mice with 
RNF5 presence or absence (RNF5WT/CFTR∆F508 and RNF5KO/CFTR∆F508, respectively), and ROC 
curve analysis identified a cut-off value of ≤ 2.9 g (i.e. < 3 g). Comparison of frequencies of mice with body 
weight less <3 g. was performed based on the Fisher’s exact test (as the expected frequencies were less than 
5), followed by Bonferroni’s correction. A symbol indicates a significant difference compared to Group 4; 
**P < 0.01.
Fecal biliary acids excretion (nmol/day* g)
Group 1 Group 2 Group 3 Group 4
RNF5WT/CFTRWT RNF5WT/CFTR∆F508 RNF5KO/CFTRWT RNF5KO/CFTR∆F508
Cholic acid 19 (5.3–108) 295 (117–446)** 6.7 (0.2–104) 82 (38–235)§
Chenodeoxycholic acid 1.2 (0.3–5.6) 21.8 (6.1–58)** 0.6 (0.01–8.7) 11 (2.5–46)
Total primary biliary acids 21 (5.9–113) 331 (123–468)** 7.1 (0.2–112) 97 (40–281)§
Deoxycholic acid 59 (15–186) 32 (10–132) 31 (0.7–368) 1.4 (1.0–21)§
Lithocholic acid 5.2 (1.4–16) 1.2 (0.4–5.4)* 3.5 (0.1–23) 0.1 (0.1–0.6)§§
Urso+ Hyodeoxycholic acid 6.8 (1.6–23) 5.9 (2.1–19) 3.9 (0.1–38) 1.9 (0.6–6.7)§
Total secondary biliary acids 73 (18–221) 39 (13–157) 40 (0.8–429) 3.9 (1.6–29)§
Glycocholic acid 0.1 (0.01–0.3) 2.0 (0.6–3.7)*** 0.02 (0.00–0.4) 0.5 (0.2–1.5)§
Taurocholic acid 3.8 (1.0–21) 93 (32–220)** 1.5 (0.02–25) 13 (7.9–108)
Taurochenodeoxycholic acid 1.8 (0.7–11) 1.3 (0.3–9.2) 1.1 (0.02–13) 0.3 (0.02–9.2)
Taurodeoxycholic acid 1.0 (0.1–2.6) 21 (4.1–32)** 0.3 (0.00–4.5) 1.6 (0.00–13)§
Taurolithocholic acid 0.1 (0.1–0.8) 0.2 (0.03–0.7) 0.1 (0.00–1.1) 0.04 (0.01–0.2)
Total conjugated biliary acids 6.9 (1.9–36) 120 (38–250)** 3.1 (0.1–44) 15 (9.6–121)
Table 2.  Fecal biliary acids excretion. Values are medians (min–max); n = 7–10. Littermates are males and 
females, 15–18 wk of age, of C57BL/6J genetic background. Comparison of values was then performed using 
the non-parametric Kruskal-Wallis ANOVA test, followed by the Mann-Whitney U test and Bonferroni’s 
correction. Symbols indicate a significant difference versus Group 1; *P < 0.05; **P < 0.01; ***P < 0.001; or 
versus Group 2; §P < 0.05; §§P < 0.01.
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bronchial epithelia from non-CF vs. CF patients, we performed immunohistochemistry experiments on 
paraformaldehyde-fixed, paraffin-embedded lung tissues (Fig. 6). Immunostaining with RNF5 antibody 
revealed that, in CF patients bearing the F508del mutation, a cytoplasmic granular positivity, with para-
nuclear reinforcement, is present in bronchial epithelial cells, with a marked positivity in the apical mem-
brane beneath the cilia. Differently, in bronchial epithelium of control patients (diagnosed as pulmonary 
Figure 5. Electrophysiological evaluation of CFTR-mediated activity in mice duodenum.  
A. Representative traces of equivalent short-circuit currents obtained from continuous recordings of 
transepithelial potential as a function of time obtained from Ussing chamber experiments on mouse 
duodenum. During recordings tissues were acutely treated with forskolin (10 μ M) and chromanol 293B 
(10 μ M). B. Summary of equivalent cAMP-dependent ∆Isc in mice of indicated genotypes. Data are 
expressed as means ± SEM, n = 6–10. Significant differences between data of ∆Isc (RNF5WT/CFTR∆F508 
vs. RNF5KO/CFTR∆F508) were calculated using Student’s t test. The symbol indicates statistical significance 
versus the RNF5WT/CFTRWT mice group: *P < 0.05.
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fibrosis), there is a more diffuse and intense cytoplasmic positivity with paranuclear reinforcement with 
only mild positivity proximal to the cilia (Fig.  6). Semi-quantitative scoring of the signal was assessed 
on the basis of intensity of RNF5 immunostaining at the apical side and in the cytoplasm and reported 
in Table 3.
Discussion
Pharmacological rescue of processing and trafficking defects caused by the CFTR F508del mutation is 
a critical goal in CF research. This outcome may be achieved by using pharmacological chaperones that 
directly interact with mutant CFTR to improve its folding and enhance its stability or by blocking activ-
ity of proteins that perturb trafficking and promote its premature degradation19,20. Various proteins are 
known to affect mutant CFTR maturation/degradation, including proteins of the ubiquitin/proteasome 
system (RMA1/RNF5, CHIP, DERLIN-1, and NEDD4L), molecular chaperones (AHA-1), proteins of the 
sumoylation pathway (UBC9), and peripheral scaffolding proteins (NHERF1)21–23,26,30,34,38,53. Here, our 
goal was to compare the therapeutic relevance of these targets using gene silencing approaches together 
with functional and biochemical evaluation of F508del rescue, and to evaluate in vivo efficacy of target 
modulation. In particular, we were interested in RNF5, since it acts at early stages of F508del-CFTR 
biosynthesis. Indeed, early folding defects occurring upon translation of the CFTR nucleotide binding 
Figure 6. Differential RNF5 expression in human bronchial epithelium of non-CF vs. CF patients. 
Representative micrographs illustrating immunostain with RNF5 antibody and counterstain with 
hematoxylin (100X magnification). a-b-c: bronchial epithelium of CF patients bearing the F508del mutation; 
d-e-f: bronchial epithelium of control (non-CF) patients (diagnosed as pulmonary fibrosis).
Patient ID 
(photo ID)
Positivity at the 
apical membrane 
(beneath cilia)
Cytoplasmic 
positivity and nuclear 
reinforcement
CF-1 (a) 3 1
CF-2 (b) 3 1
CF-3 (c) 3 1
control-1 (d) 1 3
control-2 (e) 0 1
control-3 (f) 1 2
Table 3.  Semi-quantitative scoring of the signal of RNF5 immunostaining. Scoring was assessed on 
the basis of positivity of the immunostaining at the proximal and cytoplasmic level: 0 = absent; 1 = mild, 
granular; 2 = moderate; 3 = intense, diffuse.
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domain 1 (NBD1) are sensed by the RNF5 ubiquitin ligase complex21. We report that RNF5 knockdown 
is particularly effective in rescuing mutant CFTR at the functional level. Although a more effective treat-
ment was UBC9 silencing, in vivo suppression of UBC9 is not feasible, due to its pleiotropic effects on the 
overall sumoylation system. Correspondingly, ubc9-deficient mouse embryos die early in development54. 
Intriguingly, our biochemical analysis revealed that RNF5-dependent rescue was based on increased 
expression and trafficking of the immature form of CFTR protein (band B) to the plasma membrane 
through a non-canonical route dependent on GRASP protein activity43. Specifically, we demonstrate that 
GRASP65 plays a major role in trafficking of partially glycosylated CFTR to cell surface.
In functional assays we observed an additive/synergistic effect of combining VX-809, a known 
F508del-CFTR corrector18, with RNF5 knockdown. Previously, VX-809 was found to correct 
F508del-CFTR during its synthesis55, hence at a stage when RNF5 is also believed to be involved21. 
Therefore, it was particularly interesting to check if the two interventions had additive effects or not. 
Our functional analysis reveals that pharmacological correction with VX-809 is additive with RNF5 
knockdown. We expected this result to be due to a cooperative effect on F508del-CFTR protein matura-
tion. Indeed, it is possible to hypothesize that blocking mutant CFTR degradation by RNF5 knockdown 
provides greater substrate availability for VX-809 to act as a pharmacological chaperone. This sequential 
mechanism should synergistically enhance mutant CFTR maturation. Nonetheless, biochemical analysis 
revealed that combined drug treatment and RNF5 silencing increased CFTR bands C and B, suggesting 
that each manipulation affects distinct pools of mutant CFTR. These outcomes raise the intriguing pos-
sibility that blocking mutant F508del-CFTR degradation by silencing RNF5 could induce trafficking of 
the immature form by the GRASP system. Concurrent treatment with VX-809 would impact this process 
but favor transport of a different CFTR pool to the Golgi and then to the plasma membrane.
Our observations in immortalized bronchial epithelial cells were validated using genetic RNF5KO and 
CFTR∆F508 animals. Homozygous F508del-CFTR (CFTR∆F508) mice are susceptible to gastrointestinal 
obstruction and show consistent intestinal malabsorption that dramatically reduces body weight46,48,49, a 
significantly reduced intestinal cAMP-induced chloride and bicarbonate transport response46,56, abnor-
mal intestinal mucus secretion4,57, a higher fecal biliary acids secretion46,48,49. Similar to the human var-
iant, functional correction of murine F508del CFTR by low temperature has been shown in biliary duct 
cells and intestinal biopsies in this model45,58. In addition functional correction by proteasome inhibitors 
in intestinal biopsies58 and folding correctors in intestinal organoids has been documented59, showing 
the validity of this model for our purpose. We found that in vivo RNF5 suppression ameliorated these 
defects in CFTR∆F508 model mice. In particular, markedly reduced body weight, seen in approximately 
27% of CFTR∆F508 animals, was no longer apparent following RNF5 knockout, although overall mean 
body weight did not increase. We can speculate that there are individual differences regarding the impact 
of the relatively increased CFTR activity on body weight in RNF5KO/CFTR∆F508 animals. In vivo RNF5 
suppression also reduced the extent of fecal biliary acids excretion in these animals. Conjugated bile 
acids are mainly in their deprotonated form in the duodenum, so that they are more water soluble and 
able to fulfill their physiologic function of emulsifying fats. Clarke and colleagues demonstrated that in 
CF mice there is an acidification of the duodenum, resulting from reduced duodenal and pancreatic 
CFTR-mediated bicarbonate secretion60. Lowering of duodenal pH possibly favors conversion of con-
jugated biliary acids to their protonated form, thus making them less water soluble and more prone to 
precipitation and excretion in stools. We can speculate that relatively increased CFTR activity seen in 
RNF5KO/CFTR∆F508 animals is sufficient to limit duodenal acidification, thus avoiding conjugated 
biliary salt precipitation and improving intestinal absorption.
Our in vivo data provide strong validation of biochemical and biophysical analysis performed in cul-
tured cells and clearly indicate the benefits of RNF5 loss. Notably, our in vivo assessment was performed 
in the absence of VX-809. In addition, we could also demonstrate differential RNF5 expression/localiza-
tion in human bronchial epithelial cells from non-CF and CF patients. Indeed, a deregulation of RNF5 
expression and localization was described in different degenerative pathologies including myositis47 and 
Parkinson’s disease52. The increase in RNF5 expression seen in these degenerative diseases could be a 
consequence of ER overload and/or ERAD dysfunction47. We can speculate that ER overload caused by 
F508del-CFTR might result in RNF5 upregulation in a similar way.
These findings provide a strong basis for development of RNF5-targeting molecules that could effec-
tively inhibit its activity in vivo. Such inhibitors should ameliorate key pathophysiological phenotypes 
of patients bearing the F508del mutation. Furthermore, testing of RNF5-targeting molecules in combi-
nation with correctors could reveal additional therapeutic benefits. Our work focuses F508del-CFTR; 
however, it is also important to assess the effect of RNF5-targeting molecules on other CFTR mutants, 
having trafficking defect, seen in CF patients.
Methods
Cell culture. CFBE41o− cells stably expressing F508del-CFTR and the halide-sensitive yellow fluores-
cent protein (HS-YFP) YFP-H148Q/I152L were generated as previously described27. The culture medium 
was as follows: MEM supplemented with 10% fetal calf serum, 2 mM L-glutamine, 100 U/ml penicil-
lin, and 100 μ g/ml streptomycin. For fluorescence assays of CFTR activity, CFBE41o− cells were plated 
(50,000 cells/well) on clear-bottom 96-well black microplates (Corning Life Sciences, Acton, MA).
www.nature.com/scientificreports/
13Scientific RepoRts | 5:12138 | DOi: 10.1038/srep12138
Fluorescence assay for CFTR activity. At the time of the assay, cells were washed with PBS [contain-
ing (in mM) 137 NaCl, 2.7 KCl, 8.1 Na2HPO4, 1.5 KH2PO4, 1 CaCl2, and 0.5 MgCl2] and then incubated 
for 25 min with PBS containing forskolin (20 μ M) plus genistein (50 μ M). Cells were then transferred 
to a microplate reader (FluoStar Galaxy; BMG Labtech, Offenburg, Germany) for CFTR activity deter-
mination. The plate reader was equipped with high-quality excitation (HQ500/20X: 500 ± 10 nm) and 
emission (HQ535/30M: 535 ± 15 nm) filters for YFP (Chroma Technology). Each assay consisted of a 
continuous 14-s fluorescence reading with 2 s before and 12 s after injection of an iodide-containing solu-
tion (PBS with Cl− replaced by I−; final I− concentration 100 mM). Data were normalized to the initial 
background-subtracted fluorescence. To determine I− influx rate, the final 11 s of the data for each well 
were fitted with an exponential function to extrapolate initial slope (dF/dt).
siRNA library screening. Conditions established for high-throughput siRNA transfection in a 
96-well format were as follows: CFBE41o− cells expressing F508del-CFTR and the HS-YFP were reverse 
transfected with 10 nM (final concentration) siRNAs using lipofectamine 2000 as transfection agent. 
Twenty-four hours after transfection and plating, the medium was changed and the cells were incubated 
at 37 °C for additional 24 hours, prior to proceeding with the functional HS-YFP-based assay.
Depending on availability, we utilized siRNA molecules from Dharmacon (pools containing three 
different duplexes per target) or from Sigma (four different duplexes per target). Results were confirmed 
using Stealth siRNA molecules from Life Technologies (three duplexes per target). Sequences and/or 
catalog numbers of siRNAs will be provided upon request. Target silencing was confirmed by evaluating 
expression of the target mRNA.
Evaluation of target mRNA level. To evaluate CFBE41o− cell mRNAs, we extracted total RNA using 
both Trizol reagent (Gibco–BRL) and an RNeasy Mini Kit (Qiagen), both following the manufacturers’ 
instructions. One μ g of spectrophotometer-quantified RNA was retro-transcribed using an iScript RT kit 
(Biorad). Real-time quantitative PCR (RT-qPCR) was carried out using inventoried Assays-on-Demand 
provided by Applied Biosystems. The following assays were used: CBX4 (Hs00186344_m1), 
CFTR (Hs00357011_m1), DERLIN-1 (Hs00919233_m1), GRASP55 (Hs00963853_m1), GRASP65 
(Hs00961264_m1), HDAC7 (Hs00248789_m1), PIAS3 (Hs00180666_m1), PSMD2 (Hs01092070_g1), 
RNF5 (Hs00359834_g1), UBC9 (Hs00163336_m1). Beta2-microglobulin (Hs00187842_m1) served as 
housekeeping mRNA to normalize transcript abundance. RT-qPCR was performed using an IQ5 Realtime 
PCR Detection System (BioRad). Cycling conditions were: 3 min hot start at 95 °C, followed by 40 cycles 
of denaturation at 95 °C for 30 s, and annealing and extension at 60 °C for 30 s. mRNA was quantified 
using the comparative CT Method. Each sample was run in triplicate, and data were analyzed using IQ5 
Optical System software (BioRad). Changes in transcript levels were quantified using the comparative 
CT Method (Sequence Detection System Chemistry Guide, Applied Biosystems).
Cell surface biotinylation assay. Parental CFBE41o− cells, CFBE41o− cells expressing native CFTR, 
or CFBE41o− cells expressing F508del CFTR were seeded on 100 mm dishes and reverse-transfected with 
30 nM (final concentration) non-targeting (NT) control siRNAs or siRNAs against selected targets. The 
day after, cells were incubated with vehicle alone (DMSO) or with VX-809 (1 μ M). A cell surface biotiny-
lation assay was performed 24 hr later. Briefly, cells were washed twice with ice-cold PBS and incubated 
twice with biotin (0.35 mg/ml in PBS) for 25 min each time on a shaker at 4 °C. After three washes in 
PBS, biotin was quenched with two washes in NH4Cl solution (50 mM in PBS, 15 min each) on a shaker 
at 4 °C. Cells were then washed three times in PBS without Ca2+ and Mg2+ and then scraped into Lysis 
Buffer (50 mM Hepes pH 7, 150 mM NaCl, 1% Glycerol, 1% Triton 100X, 1.5 mM MgCl2, 5 mM EGTA). 
Cell lysates were collected in an Eppendorf tube and rocked for 30 min at 4 °C. Nuclei were then pelleted 
by centrifugation at 10000 rpm at 4 °C for 20 min. Supernatant protein concentration was calculated using 
the BCA assay (Euroclone) following the manufacturer’s instructions. Then, an aliquot of supernatants 
corresponding to 600 μ g of proteins was precipitated by rotating 6 hr at 4 °C with high capacity streptavi-
din agarose resin (Thermo Fischer Scientific. Inc), following the manufacturer’s recommendation. The 
resin was then washed with the following solutions: once with Lysis Buffer, twice with Buffer 1 (150 mM 
Nacl, 20 mM Tris-HCl, pH 8, 5 mM EDTA, 1% Triton X-100, 0.2% BSA), once with Buffer 3 (150 mM 
Nacl, 20 mM Tris-HCl, pH 8, 5 mM EDTA, 0.5% Triton X-100), and once with Buffer 4 (50 mM Tris-HCl, 
pH 8). Biotinylated proteins were eluted from the resin with reducing Sample Buffer 4X and 30 μ l of each 
sample were separated on a 4-to-12% gradient NuPAGE Bis-Tris gel (Life Technologies) and analyzed 
by Western blotting.
Western blot. Cells silenced with indicated siRNAs (30 nM final concentration) were grown to con-
fluence on 60-mm diameter dishes and lysed in RIPA buffer containing a complete protease inhibi-
tor (Roche). Lysate protein concentration was calculated using the BCA assay (Euroclone) following 
the manufacturer’s instructions. Equal amounts of protein (30 μ g total per lysate) were separated on 
4-to-12% gradient NuPAGE Bis-Tris gels (Life Tecnologies) and analyzed by Western blotting. Proteins 
were detected using one of the following primary antibodies: mouse monoclonal anti-CFTR antibody 
(596, Cystic Fibrosis Foundation Therapeutics, University of North Carolina, Chapel Hill); mouse mon-
oclonal anti Na+/K+ ATPase α 1 (cl. C464.6); rabbit monoclonal anti-calnexin antibody (abcam); rabbit 
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polyclonal anti-14-3-3 epsilon antibody (abcam); goat polyclonal anti-actin antibody (cl. I-19, sc-1616, 
Santa Cruz Biotechnology, Inc) followed by horseradish peroxidase (HRP)-conjugated anti-mouse IgG 
(Biorad) or HRP-conjugated anti-rabbit IgG (Merk Millipore) or HRP-conjugated anti-goat IgG. Proteins 
were visualized by chemiluminescence using the SuperSignal West Femto Substrate (Thermo Scientific). 
Chemiluminescence was monitored using the Molecular Imager ChemiDoc XRS System. Images were 
analyzed with ImageJ software (National Institutes of Health). CFTR bands were analyzed as ROI, 
normalized against the actin loading control. Data are presented as means ± SEM of 3–5 independent 
experiments.
Animals. RNF5 knockout mice47 in C57BL/6J genetic background and recombinant mice bearing the 
F508del CFTR mutation (Cftrtm1eur)44,45 backcrossed to C57BL/6J46 were crossed to establish a colony of 
double knockout/transgenic mice on a C57BL/6J background and housed in a standard animal facility 
with solid food (Teklad Global 18% Protein Rodent Diet, code 2018; Harlan Laboratories) and sterilized 
water ad libitum. Briefly, we crossbred Rnf5−/−mice with Cftr+/F508del animals to obtain double heterozy-
gous (Rnf5+/−, Cftr+/F508del) mice, then, we intercrossed double heterozygous animals. According to the 
genotype, their offspring was divided into four groups: 1) RNF5WT/CFTRWT (Rnf5+/+ or +/−, Cftr+/+ 
or +/F508del) animals; 2) RNF5WT/CFTR∆F508 ( Rnf5+/+ or +/−, CftrF508del/F508del) animals; 3) RNF5KO/
CFTRWT (Rnf5−/−, Cftr+/+ or +/F508del) animals; and 4) RNF5KO/CFTR∆F508 ( Rnf5−/−, CftrF508del/F508del) 
animals. Body weights of female (50%) and male (50%) animals were measured nine days after birth 
using a 2-digit precision balance. Feces were collected for 96 hr from female (50%) and male (50%) mice 
at 15–18 weeks of age. For short-circuit current measurements, 8-week-old female (50%) and male (50%) 
mice were sacrificed in a CO2 chamber.
Mouse genotyping. Genomic DNA was isolated from the mouse tails, using 5’PRIME Kit 
(Eppendorf), according to the protocol. To detect the F508del-CFTR allele, PCR was carried out in a 
total volume of 25 μ l under the following conditions: 94 °C for 5 min for 1 cycle, followed by 35 cycles of 
94 °C for 60 s, 52 °C for 60 s and 72 °C for 30 s, using primers flanking mouse CFTR exon 10 (CF-P580: 
GGACGCAAAGAAAGGGATAAG; CF-P581: CACAACACTGACACAAGTAGC). The final reaction 
mixture contained 100 ng of genomic DNA plus Taq Polymerase Master Mix (WWR). Digestion reac-
tions consisting of 10 μ l of PCR product, Ssp1 buffer (10X) and 2U of SspI enzyme (Biolabs NewEngland) 
in a final volume of 15 μ l, were incubated for 3 hr at 37 °C and analyzed by 1.5% agarose gel electropho-
resis. Digested wild-type PCR products are 308 bp, while the F508del mutation creates a SspI restriction 
site, which when cleaved in homozygotes produces bands of 184 and 124 bp. Heterozygotes show bands 
of 308, 184 and 124 bp.
To genotype wild-type and mutant RNF5 alleles, PCR was carried out in 25 μ l reactions as follows: 
94 °C for 5 min for 1 cycle, followed by 35 cycles of 94 °C for 30 s, 67 °C for 90 s and 72 °C for 30 s. The final 
reaction mixture contained 100 ng genomic DNA plus Taq Polymerase Master Mix (WWR) and 650 mM 
betaine (Sigma). Primers used for PCR were as follows: KO-F: GCCAGCTGAAGGTGAGGGACTGGAC, 
and WT-R: ACACGATGCTGAGGGGAGCTGCAG for the wild-type allele and KO-F and KO-R: 
TGCGAGGCCAGAGGCCACTTGTGTAGC for the mutated allele. The PCR products were 1700 bp.
Analysis of fecal biliary acids. Bile salts and acids analytical standards and LC-MS grade solvents 
were purchased from Sigma Aldrich (Milano, Italy). Instruments, software and UPLC columns were pur-
chased from Waters Inc. (Milford, MA, USA). Bile acids levels in mouse feces were assessed as previously 
described61 with minor modifications. For sample preparation, feces for each mouse were pooled and 
oven-dried at 45 °C for 96 hr, then 500 mg feces per sample were extracted by homogenization with 4 ml 
of a 70/30 ethanol/water solution spiked with cholanic acid to a final concentration of 2.5 μ M as inter-
nal standard (I.S.) and then sonicated 1 hr at room temperature. Samples were then centrifuged 20 min 
at 9000 g, and 100 μ l supernatant was transferred into a 350 μ l, 96-well plate and diluted with 100 μ l of 
eluant A. A 4 μ l aliquot of supernatant was injected into the LC-MS/MS system for analysis. A 9-points 
calibration curve of authentic bile acid and salts analytical standard was also prepared in the 10 nM to 
100 μM range. Calibrators were processed as described above for the samples and analyzed.
Samples were then analyzed on an Acquity UPLC-TQD LC-MS system. Analytes were sepa-
rated on a BEH HSS C18 reversed-phase column (2.1 × 100 mm, 1.7 μ m particle size). Eluants were: 
A = water + 0.1% ammonia and B = ACN + 0.1% ammonia. Flow rate was set to 0.5 ml/min with the 
following gradient profile: 0 to 0.5 min, 5–15% B; 0.5 to 3.5 min, 15–48% B; 3.5 to 4 min, 48–100% B; 
hold at 100% B for 0.5 min; and then system is reconditioned to 5% B for 1 min. Injection volume was 
set to 4 μ l. As MS parameters, source gas flow and temperature were set to 450 L/hr and 400 °C, respec-
tively, and source temperature was set to 90 °C. Spray voltage (ESI-) was set to 2.0 kV and cone voltage to 
50 eV. Analytes were quantified on the basis of their pseudo-MRM traces, setting the quasi molecular ion 
m/z value (as [M-H]−) as both precursor and daughter ion for each MRM transition. Collision energy 
was set to 5 eV for all transitions. Sample concentration was evaluated on the basis of the analyte to I.S. 
peak area ratio and compared with standard curve peak areas. Data were quantitatively analyzed used 
Targetlynx software.
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Intestinal tissue isolation and Ussing chamber measurements. After animals were euthanized, 
a duodenum segment was excised, rinsed with PBS, and cut open lengthwise through the mesenteric 
border. Tissue specimens were mounted on a tissue-holding slider (P2303, aperture 0.1 cm2) and placed 
in an Ussing chamber (Physiologic Instruments Inc. San Diego, CA, USA). The solution bathing the api-
cal and basolateral hemi-chambers was continuously gassed with 5% CO2 and 95% O2 and kept at 37 °C 
throughout the experiment. That solution consisted of (in mM): 120 NaCl, 25 NaHCO3, 3.3 KH2PO4, 0.8 
K2HPO4, 1.2 MgCl2, 1.2 CaCl2 and 10 D-Glucose.
The transepithelial potential difference referred to the serosal side was measured using a VCC MC2 
amplifier (Physiologic Instrument Inc., San Diego, CA, USA). Current was clamped to 0 μ A, and 200 ms 
pulses of ± 1 μ A were passed across the tissue at 1 s intervals. The transepithelial potential difference was 
recorded using a Lab-Trax-4/16 4-channel data acquisition interface and the Data-Trax data recording 
and analysis software (World Precision Instruments, Inc. Berlin, Germany).
Measurements of potential difference between the mucosal and serosal compartment (Vte) allowed 
calculation of tissue resistance and equivalent short-circuit current (Isc). Changes in Isc after treatments, 
known as ∆Isc values, represent the magnitude of a given flux that was either already present and abol-
ished by a specific drug or a flux that was absent but induced by a given treatment or agonist. The ∆Isc 
value for cAMP-induced CFTR-mediated chloride secretion was calculated as Isc after addition of 10 μ M 
forskolin minus Isc after subsequent addition of 10 μ M chromanol 293B (trans-N-[6-Cyano-3,4-dihydro-
3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl]-N-methyl-ethanesulfonamide; Sigma Aldrich)50. In this 
way, anion secretion generates negative ∆Isc values.
Immunohistochemistry. Immunostaining to detect RNF5 protein was performed using estab-
lished protocols and reagents47,62. Briefly, sections from non-CF or CF patients, deriving from 
paraformaldehyde-fixed, paraffin-embedded lung tissues, were rehydrated by standard methods. Antigen 
retrieval was performed using Dako target retrieval solution, and endogenous peroxidase was quenched 
by incubation with 3% hydrogen peroxide for 30 min. Specimens were incubated with anti-RNF5 antibod-
ies (1:200) diluted in Dako antibody diluent overnight at 4 °C. Slides were then washed three times with 
PBS/Tween-20 and incubated with Dako Labelled Polymer-HRP for 1 h at room temperature. After three 
washes with PBS/Tween-20, samples were developed with DAB and counterstained with hematoxylin.
Statistics. Due to the fact that more than 2 groups were to be compared, the Analysis of Variance 
(ANOVA), followed by a post-hoc test was used in order to avoid “multiple comparisons error”. In the 
case of normally distributed quantitative variables, a parametric ANOVA was performed whereas when 
the quantitative variables were skewed, the non-parametric ANOVA (Kruskal-Wallis test) was applied. 
The Kolmogorov-Smirnov test was used to evaluate the assumption of normality.
Statistical significance of the effect of single siRNA treatments on CFTR activity or expression in 
CFBE41o- cells was tested by parametric one-way analysis of variance (ANOVA) followed by the Dunnet 
multiple comparisons test (all groups against the control group) as post-hoc test. In the case of combina-
tion of siRNAs against more than one target, statistical significance was verified by ANOVA followed by 
the Tukey test (for multiple comparisons) as post-hoc test.
Homoscedasticity of mouse body weight distributions was verified by using the Hartley Fmax test. The 
quantitative variable “Weight” was dichotomized between mice with RNF5 presence or absence using 
the analysis of the ROC curve method; a cut-off value of ≤ 2.9 g (i.e. < 3 g) was obtained. Comparison 
of frequencies of mice with body weight less than 3 grams was performed based on the Fisher’s exact 
test as the expected frequencies were less than 5, and the post-hoc comparison was made by applying 
Bonferroni’s correction, and the P value was indicated as P(B).
Values of biliary acids concentration in stools were first tested using Grubb’s test to identify outliers. 
Comparison of values was then performed using the non-parametric Kruskal-Wallis ANOVA test, fol-
lowed by the post-hoc Mann-Whitney U test with Bonferroni’s correction.
Significant differences between data of short-circuit currents were calculated using Student’s t test as 
the comparison was performed between two groups.
Normally distributed data are expressed as mean ± SEM, while skewed distributed data are expressed 
as median (min-max), and significances are two-sided. Differences were considered statistically signifi-
cant when P < 0.05.
Study approval. The experimental procedures performed during the animal studies were carried out 
in accordance with the approved guidelines; and were reviewed and approved by the licensing and ethical 
committee of IRCCS San Martino–IST (Genoa, Italy), and by the Italian Ministry of Health.
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